Randomized Trial: Remdesivir Not Beneficial for Adults with Severe COVID-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial – The Lancet

Commentaries: First randomized trial of remdesivir suggests antiviral drug is not associated with significant clinical benefits, more research needed – The Lancet AND Expert reaction to trial of remdesivir in adults – Science Media Centre

See also: [Not Published Yet] NIH Study Shows Remdesivir Accelerates Recovery from Advanced COVID-19

Related Commentary on Twitter

With all the hype about Remdesivir today @TheLancet has decided to lift the embargo and release this placebo-controlled multicenter study done in China that showed no benefit https://t.co/ZdmKfnWLyw

— Carlos del Rio (@CarlosdelRio7) April 29, 2020